Skip to main content
An official website of the United States government

Large Study Confirms HPV Vaccine Prevents Cervical Cancer

, by NCI Staff

Image of a girl being vaccinated.

In what many global health leaders are calling a milestone study, researchers in Sweden have confirmed that widespread use of the human papillomavirus (HPV) vaccine dramatically reduces the number of women who will develop cervical cancer.

In the study of nearly 1.7 million women, the vaccine’s efficacy was particularly pronounced among girls vaccinated before age 17, among whom there was a nearly 90% reduction in cervical cancer incidence during the 11-year study period (2006 through 2017) compared with the incidence in women who had not been vaccinated.

It’s taken some time, but the findings from the Swedish study complete the story of the HPV vaccine," said Aimée R. Kreimer, Ph.D., senior investigator in the Infections and Immunoepidemiology Branch. “This provides the final key piece of evidence in the pathway from [HPV] infection to cancer," she said, "and HPV vaccination protects against all of it.”

Read the full NCI Cancer Current Blog post.

< Older Post

Exploring E-cigarette Use Among U.S. Adults

Newer Post >

Standardizing the Definition of Aggressive Prostate Cancer for Etiologic Studies

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Large Study Confirms HPV Vaccine Prevents Cervical Cancer was originally published by the National Cancer Institute.”